Invariant NKT cells increase drug-induced osteosarcoma cell death

British Journal of Pharmacology

Volumn 167, Issue 7, 2012, Pages 1533-1549

  Fallarini, S ^a   Paoletti, T ^a   Orsi Battaglini, N ^b   Lombardi, G ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

cisplatin; combination therapy; doxorubicin; iNKT cells; methotrexate; osteosarcoma

Indexed keywords

CD14 ANTIGEN; CD19 ANTIGEN; CD1B ANTIGEN; CISPLATIN; DOXORUBICIN; FAS ANTIGEN; FAS LIGAND; GRANZYME B; MESSENGER RNA; METHOTREXATE; PERFORIN;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CD1B ANTIGEN GENE; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL DEATH; CELL EXPANSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MESENCHYMAL STEM CELL; NATURAL KILLER T CELL; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELLS, CULTURED; CISPLATIN; DOXORUBICIN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; METHOTREXATE; NATURAL KILLER T-CELLS; OSTEOSARCOMA;

EID: 84868638412     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02108.x     Document Type: Article

References (74)

1. Bagnara D, Ibatici A, Corselli M, Sessarego N, Tenca C, De Santanna A, (2009). Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms. Haematologica 94: 967-974.
2. Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, et al,. (2009). The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol 39: 1046-1055.
3. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, et al,. (1998). CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 188: 1521-1528.
4. Buddingh EP, Schilham MW, Ruslan SE, Berghuis D, Szuhai K, Suurmond J, et al,. (2011). Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 60: 575-586.
5. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, et al,. (1999). Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163: 4647-4650.
6. Chávez-Galán L, Arenas-Del Angel MC, Zenteno E, Chávez R, Lascurain R, (2009). Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 6: 15-25.
7. Chou AJ, Gorlick R, (2006). Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6: 1075-1085.
8. Clark JC, Dass CR, Choong PF, (2008). A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 134: 281-297.
9. Cole PD, Smith AK, Kamen BA, (2002). Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs. Cancer Chemother Pharmacol 50: 111-116.
10. Croudace JE, Curbishley SM, Mura M, Willcox CR, Illarionov PA, Besra GS, et al,. (2008). Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide. BMC Immunol 9: 71.
11. Crough T, Purdie DM, Okai M, Maksoud A, Nieda M, Nicol AJ, (2004). Modulation of human Valpha24(+) Vbeta11(+) NKT cells by age, malignancy and conventional anticancer therapies. Br J Cancer 91: 1880-1886.
12. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG, et al,. (2005). Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 202: 1279-1288.
13. Decker S, Winkelmann W, Nies B, van Valen F, (1999). Cytotoxic effect of methotrexate and its solvent on osteosarcoma cells in vitro. J Bone Joint Surg Br 81: 545-551.
14. Dhodapkar MV, Richter J, (2011). Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. Clin Immunol 140: 160-166.
15. Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, Dhodapkar KM, et al,. (2003). A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197: 1667-1676.
16. Duan X, Zhou Z, Jia SF, Colvin M, Lafleur EA, Kleinerman ES, (2004). Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway. Clin Cancer Res 10: 777-783.
17. Eberl G, MacDonald HR, (2000). Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 30: 985-992.
18. Exley MA, Lynch L, Varghese B, Nowak M, Alatrakchi N, Balk SP, (2011). Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumour-induced defects. Clin Immunol 140: 184-195.
19. Fais F, Morabito F, Stelitano C, Callea V, Zanardi S, Scudeletti M, et al,. (2004). CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer 109: 402-411.
20. Fallarini S, Paoletti T, Panza L, Lombardi G, (2008). Alpha-galactosylceramide modulates the induction of indoleamine 2,3-dioxygenase in antigen presenting cells. Biochem Pharmacol 76: 738-750.
21. Fallarini S, Miglio G, Paoletti T, Minassi A, Amoruso A, Bardelli C, et al,. (2009). Clovamide and rosmarinic acid induce neuroprotective effects in in vitro models of neuronal death. Br J Pharmacol 157: 1072-1084.
22. Fallarini S, Magliulo L, Paoletti T, de Lalla C, Lombardi G, (2010). Expression of functional GPR35 in human iNKT cells. Biochem Biophys Res Commun 398: 420-425.
23. Fellenberg J, Mau H, Nedel S, Ewerbeck V, Debatin KM, (2000). Drug-induced apoptosis in osteosarcoma cell lines is mediated by caspase activation independent of CD95-receptor/ligand interaction. J Orthop Res 18: 10-17.
24. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, et al,. (2005). Italian and Scandinavian sarcoma groups. neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian sarcoma groups. J Clin Oncol 23: 8845-8852.
25. Fujii S, (2008). Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies. Trends Immunol 29: 242-249.
26. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, et al,. (2002). A phase I study of the natural killer T-cell ligand alpha- galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8: 3702-3709.
27. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L, (2004). NKT cells: what's in a name? Nat Rev Immunol 4: 231-237.
28. van den Heuvel MJ, Garg N, Van Kaer L, Haeryfar SM, (2011). NKT cell costimulation: experimental progress and therapeutic promise. Trends Mol Med 17: 65-77.
29. Hogendoorn PC, Athanasou N, Bielack S, De Alava E, Dei Tos AP, Ferrari S, et al,. (2010). ESMO/EUROBONET working group, bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21: v204-v213.
30. Ishihara S, Nieda M, Kitayama J, Osada T, Yabe T, Kikuchi A, et al,. (2000). Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro. J Immunol 165: 1659-1664.
31. Janeway KA, Grier HE, (2010). Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol 11: 670-678.
32. Johnstone EC, Lind MJ, Griffin MJ, Boddy AV, (2000). Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients. Cancer Chemother Pharmacol 46: 433-441.
33. Kronenberg M, (2005). Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23: 877-900.
34. Lake RA, Robinson BW, (2005). Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 5: 397-405.
35. Lee PT, Benlagha K, Teyton L, Bendelac A, (2002). Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 195: 637-641.
36. Lesterhuis WJ, Steer H, Lake RA, (2011). PD-L2 is predominantly expressed by Th2 cells. Mol Immunol 49: 1-3.
37. Lin H, Nieda M, Nicol AJ, (2004). Differential proliferative response of NKT cell subpopulations to in vitro stimulation in presence of different cytokines. Eur J Immunol 34: 2664-2671.
38. Lisbonne M, Hachem P, Tonanny MB, Fourneau JM, Sidobre S, Kronenberg M, et al,. (2004). In vivo activation of invariant V alpha 14 natural killer T cells by alpha-galactosylceramide sequentially induces Fas-dependent and -independent cytotoxicity. Eur J Immunol 34: 1381-1388.
39. Luksch R, Perotti D, Cefalo G, Gambacorti Passerini C, Massimino M, Spreafico F, et al,. (2003). Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori 89: 263-268.
40. Marina N, Gorlick R, (2009). Immune approaches to treating osteosarcoma. Cancer Biol Ther 8: 981-983.
41. Mattarollo SR, Kenna T, Nieda M, Nicol AJ, (2006). Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to V alpha 24+ NKT cell-mediated cytotoxicity. Int J Cancer 119: 1630-1637.
42. Metelitsa LS, (2004). Flow cytometry for natural killer T cells: multi-parameter methods for multifunctional cells. Clin Immunol 110: 267-276.
43. Metelitsa LS, (2011). Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin Immunol 140: 119-129.
44. Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC, (2003). Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 17: 1068-1077.
45. Molano A, Illarionov PA, Besra GS, Putterman C, Porcelli SA, (2008). Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase. Immunol Lett 117: 81-90.
46. Molling JW, Moreno M, van der Vliet HJ, van den Eertwegh AJ, Scheper RJ, von Blomberg BM, et al,. (2008). Invariant natural killer T cells and immunotherapy of cancer. Clin Immunol 129: 182-194.
47. Montoya CJ, Pollard D, Martinson J, Kumari K, Wasserfall C, Mulder CB, et al,. (2007). Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 122: 1-14.
48. Mori K, Rédini F, Gouin F, Cherrier B, Heymann D, (2006). Osteosarcoma: current status of immunotherapy and future trends. Oncol Rep 15: 693-700.
49. Morris ES, MacDonald KP, Rowe V, Banovic T, Kuns RD, Don AL, et al,. (2005). NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest 115: 3093-3103.
50. Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, et al,. (2006). A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 12: 6079-6086.
51. Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, et al,. (2000). Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology 99: 229-234.
52. Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y, et al,. (2001). TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 97: 2067-2074.
53. Nowak M, Arredouani MS, Tun-Kyi A, Schmidt-Wolf I, Sanda MG, Balk SP, et al,. (2010). Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide. Plos ONE 5: e11311.
54. Paoletti T, Fallarini S, Gugliesi F, Minassi A, Appendino G, Lombardi G, (2009). Anti-inflammatory and vascular protective properties of 8-prenylapigenin. Eur J Pharmacol 620: 120-130.
55. Ritter J, Bielack SS, (2010). Osteosarcoma. Ann Oncol 21 (Suppl. 7): vii320-vii325.
56. Robson H, Meyer S, Shalet SM, Anderson E, Roberts S, Eden OB, (2002). Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines. Med Pediatr Oncol 39: 573-580.
57. Rogers PR, Matsumoto A, Naidenko O, Kronenberg M, Mikayama T, Kato S, (2004). Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000. J Immunol Methods 285: 197-214.
58. Serra M, Scotlandi K, Manara MC, Maurici D, Lollini PL, De Giovanni C, et al,. (1993). Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 13: 323-329.
59. Smyth MJ, Crowe NY, Godfrey DI, (2001). NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 13: 459-463.
60. Song L, Asgharzadeh S, Salo J, Engell K, Wu HW, Sposto R, et al,. (2009). Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest 119: 1524-1536.
61. Sun J, Fu ZM, Fang CQ, Li JH, (2007). Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents. Chin Med J 120: 400-404.
62. Ta HT, Dass CR, Choong PF, Dunstan DE, (2009). Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 28: 247-263.
63. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, et al,. (2001). Loss of IFNgamma production by invariant NK T cells in advanced cancer. J Immunol 167: 4046-4050.
64. Takahashi T, Chiba S, Nieda M, Azuma T, Ishihara S, Shibata Y, et al,. (2002). Cutting edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 168: 3140-3144.
65. Taniguchi M, Tashiro T, Dashtsoodol N, Hongo N, Watarai H, (2010). The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. Int Immunol 22: 1-6.
66. Terabe M, Berzofsky JA, (2008). The role of NKT cells in tumor immunity. Adv Cancer Res 101: 277-348.
67. Terabe M, Khanna C, Bose S, Melchionda F, Mendoza A, Mackall CL, et al,. (2006). CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta. Cancer Res 66: 3869-3875.
68. Théoleyre S, Mori K, Cherrier B, Passuti N, Gouin F, Rédini F, et al,. (2005). Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer 5: 123-133.
69. Tsuda N, Murayama K, Ishida H, Matsunaga K, Komiya S, Itoh K, et al,. (2001). Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. J Orthop Res 19: 346-351.
70. van der Vliet HJ, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, van Bodegraven AA, et al,. (2001). Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 100: 144-148.
71. van der Vliet HJ, Molling JW, von Blomberg BM, Nishi N, Kölgen W, van den Eertwegh AJ, et al,. (2004). The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol 112: 8-23.
72. Whelan JS, Jinks RC, McTiernan A, Sydes MR, Hook JM, Trani L, et al,. (2012). Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European osteosarcoma intergroup randomised controlled trials. Ann Oncol 23: 1607-1616.
73. Wingender G, Krebs P, Beutler B, Kronenberg M, (2010). Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency. J Immunol 185: 2721-2729.
74. Zitvogel L, Tesniere A, Apetoh L, Ghiringhelli F, Kroemer G, (2008). Immunological aspects of anticancer chemotherapy. Bull Acad Natl Med 192: 1469-1478.